A011000 Stock Overview
A biopharmaceutical company, engages in the research, development, and contract manufacturing of nucleic acid-based biopharmaceuticals. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
GeneOne Life Science, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩2,030.00 |
| 52 Week High | ₩4,735.00 |
| 52 Week Low | ₩1,835.00 |
| Beta | -1.99 |
| 1 Month Change | -5.36% |
| 3 Month Change | -16.80% |
| 1 Year Change | -26.85% |
| 3 Year Change | -86.33% |
| 5 Year Change | 26.35% |
| Change since IPO | 141.28% |
Recent News & Updates
The Market Doesn't Like What It Sees From GeneOne Life Science, Inc.'s (KRX:011000) Revenues Yet As Shares Tumble 39%
Sep 09
Is GeneOne Life Science (KRX:011000) Using Too Much Debt?
Aug 31Recent updates
The Market Doesn't Like What It Sees From GeneOne Life Science, Inc.'s (KRX:011000) Revenues Yet As Shares Tumble 39%
Sep 09Is GeneOne Life Science (KRX:011000) Using Too Much Debt?
Aug 31Why Investors Shouldn't Be Surprised By GeneOne Life Science, Inc.'s (KRX:011000) Low P/S
Jul 26Is GeneOne Life Science (KRX:011000) Using Debt In A Risky Way?
Mar 20GeneOne Life Science (KRX:011000) Has Rewarded Shareholders With An Exceptional 855% Total Return On Their Investment
Jan 10
Shareholder Returns
| A011000 | KR Biotechs | KR Market | |
|---|---|---|---|
| 7D | -3.6% | -4.0% | -2.1% |
| 1Y | -26.8% | 16.1% | -9.0% |
Return vs Industry: A011000 underperformed the KR Biotechs industry which returned 16.1% over the past year.
Return vs Market: A011000 underperformed the KR Market which returned -9% over the past year.
Price Volatility
| A011000 volatility | |
|---|---|
| A011000 Average Weekly Movement | 7.2% |
| Biotechs Industry Average Movement | 8.7% |
| Market Average Movement | 6.6% |
| 10% most volatile stocks in KR Market | 12.7% |
| 10% least volatile stocks in KR Market | 3.3% |
Stable Share Price: A011000 has not had significant price volatility in the past 3 months compared to the KR market.
Volatility Over Time: A011000's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1976 | 46 | Young-Keun Park | www.genels.com |
GeneOne Life Science, Inc., a biopharmaceutical company, engages in the research, development, and contract manufacturing of nucleic acid-based biopharmaceuticals. Its small molecule pipeline comprises GLS-1027, which is in Phase I clinical trial for treatment of nephropathy and inflammatory diseases; GLS-1200 that is in Phase II clinical trial to treat Rhinosinusitis; GLS-1027 and GLS-1200, which is Phase II clinical trial for treatment of COVID-19. The company’s nucleic acid vaccines include GLS-3000 mRNA under feasible study and GLS-5310 DNA under phase 2 stage for the treatment of SARS-CoV-2; GLS-5100 under pre-clinical stage for prevention of herpes zoster; and GLS-5140 under pre-clinical stage for the treatment of SFTS prophylaxis.
GeneOne Life Science, Inc. Fundamentals Summary
| A011000 fundamental statistics | |
|---|---|
| Market cap | ₩164.45b |
| Earnings (TTM) | -₩72.69b |
| Revenue (TTM) | ₩37.97b |
4.3x
P/S Ratio-2.2x
P/E RatioIs A011000 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A011000 income statement (TTM) | |
|---|---|
| Revenue | ₩37.97b |
| Cost of Revenue | ₩45.99b |
| Gross Profit | -₩8.02b |
| Other Expenses | ₩64.67b |
| Earnings | -₩72.69b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -910.57 |
| Gross Margin | -21.12% |
| Net Profit Margin | -191.45% |
| Debt/Equity Ratio | 18.4% |
How did A011000 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/24 16:12 |
| End of Day Share Price | 2024/12/24 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
GeneOne Life Science, Inc. is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Reni Benjamin | Rodman & Renshaw, LLC |